Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore

Value in Health Regional Issues

Volumn 1, Issue 1, 2012, Pages 66-74

  Lopes, Gilberto ^a,b   Burke, Thomas ^c   Pellissier, James ^c   Zhang, Xu Hao ^c   Dedhiya, Seema ^d   Chan, Alexandre ^e,f  

^a Johns Hopkins Singapore   (Singapore)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Merck Sharp and Dhome ^*

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Aprepitant; Chemotherapy; Cost effectiveness; Emesis; Singapore

Indexed keywords

EID: 84984550331     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2012.03.002     Document Type: Article

References (22)

1. de Boer-Dennert M., de Wit R., Schmitz P.I., et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Bri J Can 1997, 76:1055-1061.
2. Ettinger D.S., Armstrong D.K., Barbour S., et al. NCCN Clinical Practice Guidelines: Antiemesis [Accessed August 22, 2011]. https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.
3. Dando T.M., Perry C.M. Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004, 64:777-794.
4. Curran M.P., Robinson D.M. Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 2009, 69:1853-1878.
5. Roila F., Herrstedt J., Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010, 21(Suppl. 5):v232-v243.
6. Basch E., Prestrud A.A., Hesketh P.J., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011, 29:4189-4198.
7. Emend Local Prescribing Information 2011, Singapore.
8. Approval of proposal for alendronate, aprepitant, raltegravir, levodopa with carbidopa, timolol and dorzolamide with timolol [notification] PHARMAC. http://www.pharmac.govt.nz/2009/09/03/2009-09-03%20PHARMAC%20notification%20of%20decision%20involving%20alendronate,%20aprepitant,%20raltegravir%20and%20others.pdf2009.
9. Health Insurance Review and Assessment Service: Medicine Information 2009.
10. Aprepitant for moderately emetogenic chemotherapy in patients who have had a prior episode of chemotherapy-induced nausea and vomiting [public summary document] [Accessed August 28, 2011]. http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-aprepitant-mar10.
11. Annemans L., Strens D., Lox E., et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer 2008, 16:905-915.
12. Lordick F., Ehlken B., Ihbe-Heffinger A., et al. Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany. Eur J Cancer 2007, 43:299-307.
13. Moore S., Tumeh J., Wojtanowski S., et al. Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Value Health 2007, 10:23-31.
14. Warr D.G., Hesketh P.J., Gralla R.J., et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005, 23:2822-2830.
15. Hesketh P.J., Grunberg S.M., Gralla R.J., et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clinical Oncol 2003, 21:4112-4119.
16. Poli-Bigelli S., Rodrigues-Pereira J., Carides A.D., et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003, 97:3090-3098.
17. Schmoll H.J., Aapro M.S., Poli-Bigelli S., et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006, 17:1000-1006.
18. Rapoport B.L., Jordan K., Boice J.A., et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010, 18(4):423-431.
19. Jordan K., Hinke A., Grothey A., et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007, 15:1023-1033.
20. Sun C.C., Bodurka D.C., Donato M.L., et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. Gynecol Oncol 2002, 87:118-128.
21. Avritscher E.B., Shih Y.C., Sun C.C., et al. Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol 2010, 8:242-251.
22. Currency exchange rate between Singapore Dollars and US Dollars XE: The World's Favorite Currency Site, [Accessed December 8, 2011]. http://www.xe.com/.